$0.73
-0.01 (-1.49%)
Open$0.72
Previous Close$0.74
Day High$0.75
Day Low$0.71
52W High$2.42
52W Low$0.72
Volume—
Avg Volume56.5K
Market Cap7.30M
P/E Ratio—
EPS$-1.16
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,848.8% upside
Current
$0.73
$0.73
Target
$21.60
$21.60
$19.68
$21.60 avg
$29.43
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 4.88M | 3.70M | 3.80M |
| Net Income | -10,739,751 | -7,329,220 | 985.2K |
| Profit Margin | -220.2% | -209.2% | 25.9% |
| EBITDA | -15,551,510 | -11,202,558 | 1.34M |
| Free Cash Flow | — | — | 1.13M |
| Rev Growth | +31.9% | +31.9% | +24.5% |
| Debt/Equity | 0.95 | 0.95 | 1.00 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |